PEG IFN- -2a improves QOL in hepatitis C

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.403, 2003-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PEG IFN- -2a flies ahead in chronic hepatitis C

Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

PEG IFN- -2a beats conventional therapy in hepatitis C

Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

PEG IFN- -2b plus ribavirin worth its cost in chronic hepatitis C

Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Recurrent hepatitis C virus (HCV) infection after liver transplantation "can be safely treated" with PEG interferon (IFN)- -2b and ribavirin

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

A 23% market share of new prescriptions for hepatitis C in the US has been captured by Roche's antiviral agent PEG-interferon (IFN)- -2a

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 402, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite